Koninklijke Philips N.V.

NYSE:PHG

Medical - Devices

Healthcare
$29.81 +2.17%

+$0.57 today

Market cap
$29.11B
Beta
0.93
P/E (TTM)
23.1
EPS (TTM)
$1.02
Dividend yield
3.62%
52W Low $22.20High $33.44

Volume 1.45M

Average 1.17M

PHG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Koninklijke Philips N.V.NYSE: PHG

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of €484M rose 20.4% year over year, ahead of the -2.6% change in trailing-twelve-month research & development. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.

Context

  • Research & development amounted to 9.5% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.4% holds above the trailing-twelve-month pace of -2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€484M+22.8% QoQ
Last fiscal yearDec 2025
€1.7B-2.7% YoY
LTMJun 2026
€1.72B-2.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.4%——
1 year-2.7%——
3-year CAGR-6.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
1.7B EUR
Year-over-year change
-2.7%
4-year CAGR
-1.5%

Research & Development vs competitors

How PHG compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.6% is the lowest of 10, against a peer median of +11.3%.
  • Research & development amounts to 9.7% of revenue for PHG, versus a peer median of 6.8%.
PHG Competitors
Research & Development for PHG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$3.28B USD+11.3%+1.2%6.8%
MDTMedtronic plcLTM Jul 2026$2.92B USD+4.9%+2.1%7.8%
BSXBoston Scientific CorporationLTM Jun 2026$2.15B USD+17.3%+15.8%10.3%
PHGKoninklijke Philips N.V.LTM Jun 2026€1.72B EUR-2.6%-6.7%9.7%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$1.32B USD+1.2%+7.1%6.5%
RMDResMed Inc.LTM Jun 2026$378.28M USD+14.2%+9.6%6.7%
SNNSmith & Nephew plcFY2025$346M USD+0.9%+0.1%5.6%
LIVNLivaNova PLCLTM Sep 2026$202.57M USD+14.5%+6.0%13.4%
NPCENeuroPace, Inc.LTM Mar 2026$27.64M USD+9.2%+8.3%27.8%
IRMDIRadimed CorporationLTM Mar 2026$3.31M USD+25.5%+9.3%3.8%
Peer median (excluding PHG) —+11.3%+7.1%6.8%

Competitors are the stored peer set for PHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.16B17.83B18.17B18.02B17.83B
Cost of Revenue9.99B10.63B10.72B10.25B9.78B
Gross Profit7.17B7.19B7.45B7.77B8.06B
Gross Margin41.8%40.4%41.0%43.1%45.2%
Research & Development1.81B2.09B1.89B1.75B1.7B
Selling, General & Admin4.86B5.29B5.13B5.07B4.97B
Operating Expenses6.62B8.72B7.56B7.24B6.63B
Depreciation & Amortization1.32B1.6B1.26B1.39B1.13B
EBITDA2B115M1.04B1.85B2.64B
EBITDA Margin11.6%0.6%5.7%10.3%14.8%
Operating Income553M(1.53B)(115M)529M1.42B
Operating Margin3.2%-8.6%-0.6%2.9%8.0%
Interest Income18M25M46M79M108.54M
Interest Expense164M244M306M337M332.34M
Other Income / Expenses(44M)(202M)(412M)(406M)(242M)
Income Before Tax509M(1.73B)(527M)123M1.18B
Pre-Tax Margin3.0%-9.7%-2.9%0.7%6.6%
Income Tax Expense(103M)(113M)(73M)963M282M
Net Income3.32B(1.61B)(466M)(702M)895M
Net Margin19.3%-9.0%-2.6%-3.9%5.0%
EPS (Basic)0.67(1.68)(0.49)(0.75)0.95
EPS (Diluted)0.64(1.68)(0.49)(0.75)0.93
Weighted Avg Shares907.46M952.46M948.79M933.37M962.37M
Weighted Avg Shares (Diluted)950.28M952.46M948.79M933.37M962.5M

Koninklijke Philips N.V.

NYSE:PHG

Intrinsic Alpha fair value

Locked

Current Price

$29.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.